Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arqule Inc ONE WALL STREET BURLINGTON MA 01803 USA

P: 781-994-0300 F: 781-376-6019

Description:

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche.

Key Statistics

Overview:

Market Capitalization, $K 649,655
Shares Outstanding, K 108,820
Annual Sales, $ 0 K
Annual Net Income, $ -29,200 K
Last Quarter Sales, $ 13,710 K
Last Quarter Net Income, $ 5,160 K
36-Month Beta 0.85
% of Insider Shareholders 7.90%
% of Institutional Shareholders 61.89%

Growth:

1-Year Total Return 496.19%
3-Year Total Return 257.49%
5-Year Total Return 123.60%
5-Year Revenue Growth -100.00%
5-Year Earnings Growth -116.67%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.09 on 03/05/18
Next Earnings Date 08/01/18
Earnings Per Share ttm -0.20
EPS Growth vs. Prev Qtr 171.43%
EPS Growth vs. Prev Year 150.00%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00

ARQL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -51.03
Price/Earnings to Growth N/A
Return-on-Equity (After Tax) -110.58
Return-on-Assets (Before Tax) -36.66
Net Margin % -70.49
Debt/Equity 1.50
Price/Sales 28.13
Price/Cash Flow N/A
Price/Book 22.69
Book Value/Share -0.25
Interest Coverage -18.21
Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar